Download - 20130318 衛環委員會-衛生署業務報告
-
1
8 3
() 1. 1 98
102 2 190 26 77
2 19 102 1 14 102 104
-
2
1 20 1 28
3 102 15 28 180 95
4 97 CPR+AED 222 1 5,000 36 AED CPR+AED 102 1 16 10200003971 (AED)AED
-
3
2.
1 9 17 24
2 13 8
3 15 21 28 24
() 1.
99 7 1101 78213 831
-
4
2. 101 39 1,325
3. 14 101 131 1 4,327
4. 102 (OSCE) 102 22
5. 101 16 45 103 1 1
6. 101 14
-
5
() 1. 101
14 5 31,485
2. 118 108 96 1 4,131 101 3 8,507 94 71.5% 100 5%
3. / 101 4 2 10% 658(HbA1c) 775/ 130/85 86
-
6
() 1.
101 22 292 101 56 5,186 4.31 42% 102 1 13 1,228
2. 97 7 499 1,696 95%100 1,211 96.12%101 1,221 96.8%102 1 86 97.7%99 27 100%100 40 97.5%101101 56 92.86%
3. 100 3,507 10 15.1 99 3,889 10 16.8 382 9.8% 99 2 10 100 12 101 1 12
-
7
3,461 100 46 1.3% 101 102 6
() 1. 101
198 9
2. 175 851
3. / 69
4. 102 1
5. 1 10
-
8
2 3
6. 101 12 28 102 2 1
7. 91 2012
() 1. 5 (33
25100
-
9
26) 11
2. 101 1 1 103 12 31 200 101 10 1 102 2 23 188 37 15 13 1,535
3.
4. 100
5.
6. () 1
-
10
24 98.7
2 () ()
7. 101 5 10 6 10
1 102 1 49 14 71%10
2 101622
3 101
-
11
4 101 67%
4 101 9 21 () 101 9 1 100 200 101 64%
5 150 30 60 102125
6 101 2 302 () 27,508 2,555.2
7 101 12 141,007 (101 4 ) 136,415 4,592
8 101 5 101 12 2,829 1,670 1,159
-
12
9 102 3,000 5,000 2
10 101 7-9
11 8 29
12 8
13 102
8. 1 101 6 4 6
2 95 101
3,728 3 100 69
-
13
2,488101 80102 13
4 102 () 9. 1 100 23 1
101 102 102
2 101 57 4 10 9 5 29
3 102
() 1. 102 1 8
2
2. 100 6 7
-
14
1 25
2 101 12 117 10 91 16 10 ()
3. 24 95 3 101 495 4,593
4. 15 ( 25 ) CDC 61%
5. 1 101
7 101 111 , 1 6,311 868284 102 11
2 101 3 101
-
15
11 101 3,689 1,775 1 5,826 102 7
4 101 102 16
5 1,943 ( 1,497 227 216 3)
6. (21 100 5 28 )(22) H1N1(22 100 )
7. (IRC) 7 100 1 101 12 7 8,602 10,731 8 9,333 19
-
16
14
8. () () () ()
9. 26102 3ISO
10. 102 6 ()()()()()()() IRC()
() 1. 1
101 12 282
2 101 12 207
-
17
3 101 12 191
2. 101 12 IC 36
3. 101 12 189 183
() 1. 1
HIS 101 12 55 ( 30 18 7 )
2 32 ( 23 9)(PACS)
-
18
3
100 19 101 6,906
2.
1 101 338 () 3
2 101 314 241 2 40
3 () 102 2 16 () 3 101 102 3,550
3. 101
-
19
86 101 6 5,296 1 4,078 10 4,16 2 9,517 1,904 9 1,968 1 600
4.
5. 101 401,600
6. 101 807 102 52 (27 )
7. 24 101 277 94.86%
-
20
101
8.
() 1. 1
2
()(22 )(63)(368 )
3 5 101
2. 1
-
21
99 101 1 157 52 2 157101 22
99 101 8,262 305 99 101 8,759 17,021
2 ()101 13 102 20
3. 1
97 2.3%98 5.7%99 16.3%100 21% 101 27%( 16%)97 101 11 3,202
-
22
100 6 1,675 97 3.5 101 6 4,733 100 1.1
101 9,737 3,332 CDR
2 101 311
4. 7 7 8 7 8 1 2 3 101 2 23 7 129 6 95
5.
1 (
-
23
)()101
2 101 102 6 1036
3 101 7 102 12 103 6
4
-
24
5 98 9 101 12 106 300
() 1. 99 4 1
99 3 604 101 12 206
2. ()101 12 18.58
3.
-
25
101 12 680 2.64%
4. 7 100 12 1 101 -0.36%
() 1. 1 100
4.39 4.17 5.01% 4 5,511 4 5,366 145 0.32%
2 101 1 11 (98 1 11 )4.39 4.13 5.92%(98 1 11)4 5,474 4 5,182 292 0.64%
-
26
3
2. 1
8 3 20 3 10071103 6 30 101 1 1 103 12 31 101 3 1
2 ()
3. 1 101
21.47
101620
-
27
57114C 6 43 12.83
0.572 8.527 9% 4 2 6 3% 9.099
101 1 1
2 101 3.2
3 100 8 RBRVS 37 100 9100 10 26 101 10 102
-
28
4 10250.552.22
4. (1)(2)(3) 3 101 12 387
() 1. 101 12
258 219 2. 1 101 12
3,589 2.14 13 31.8 4,755 2,274
2 101 4.3 3.53
-
29
3. 101 12 3,787 1.1
4. 1 99 10
101 12 43.4 20
2 101 6 4 101 12 14.1 4
5. (IDS)
1 48(42)
2 101 25 4-6
-
30
(1004.39101193.03)
() 1.
90 99 150 () 100 ()100 100 33,138 7.2 101 12 24 26% 8.29
2.
3. 98 12 101 193 46 101 0.12 9.9%
-
31
() 1. 100
2. 102 1 1
3. Health Technology Assessment, HTA 101 11 26 HTA
-
32
() 1. 10112572
40 2,363 242 () 160 91 102
2. 101 1,926 18 (14 22)
3. 101 12 61 637
4. 4LC/MS/MS
5. 101 1 12 50
() 1. 1 101 8 8 11
-
33
17 1 31 101 8 27 102 1 10
2 101 12 248 )10 11 98
2. 1 101
QSA 9 63.31% 101 9 13 12 983 815
2 101 9 6
-
34
101 9 12 101 9 20 101 9 12 11 20 33,550 99.8%
3 101 9 1111 18446
3. 1 101 12 45,0942 (
781 )101 37,899 100 27%
2 101 12 424
4. 1
http://fadenbook.fda. gov.tw/101 12 501 11,253
-
35
101 4 400
2 101 6 28 101 7 9
5. 1 101 1 18
101 8 9
2 100 7 21 101 7 21 () () 82
-
36
() 1. 1 (cGMP) 101 12
158 ( 10 3) 21( 146) GMP
2 PIC/S GMP 45 PIC/S GMP 102 1 1 PIC/S 43
3 (GMP) 101 12 GMP/QSD 3,596 14.7% 85.3%
2. 1 99-101 271
101 6
2 101 4 5 (REMS) 101 12
-
37
REMS 12 14 6 58
3 101 12 773 1,275 89 100%
4 101 12 80
5 99 (Global Harmonization Task ForceGHTF)(NCAR) 101 4 649 101 1,385 1,119 160
6 101 1,111 191 183 8 159 141 18 132 102 20 10 629 142 7 480
3. 6 101 6 27 3 4
-
38
4. 101 6 27
GMP GMP
5. 101 11 1
() 1. 101 10 15
(eCTD) 2. 101 12 7
3. 101 42 (approval letter)
4. 101
-
39
12 25 6
5. 101 11 29 (STED) 36
6. 22 17 2
7. 34 101 12 6 913 6 2 3 24 32 33.3%
8. WHO ICDRA
() 1.
101 1 6,216 202 1.25%
-
40
2. 101
18,22510016,6549.4%
() 1. 101 12
8,142 2 346 2 99 1 13.93% 101 12 4.71% 9.22%
2. 99 3 1,500 99 27.22% 101 12 1.76% 98 30.2% 101 14.4%
() 1. 101 827
2,318 345 159 364 280
2. 101 79 11 3 21 261
-
41
17 3. 101 121
507 99.6% 4. 101
331 271
5. GMP 101 49 GMP
6. 101 8 1 10 12 857
7. 101 300
8.
9. 101 9 5 62012
10. 101 9 14 16 16Last Year and This Year in Taiwan 2014 17 4
-
42
11. Journal of Traditional and Complementary MedicineJTCM 101 12 5 50
() 1. WHO101 9 24
102 2 16 3 13 7
2. 9 24 WHO
3. 10
4.
5. 101 9 28 10 3
-
43
6. 3
84
7.
() 1. 71
(101) 153 2 1.3(102) 3 131
2.
3. 71
4.
-
44
5.
101 5 14
6. 5
() 1. 101 1,273
751 503 7 5 2 1 (102) 3 13 15101 100 82.3 99 79.8101 207 7445302014 10 102 42 1718542008-2012 1538372030
-
45
2.
3. 101
4. 101 3 101 5 9
5. 101 4 5 8 2,490
6. 101 6
-
46
() 1. 94-100
35.6%
2. (DOTS)101 12,064 90%
3. X 101 5,513 100 4,842 99 3,874
4. (MDR) 96 5 100101 145
5.
() 1. 101 2 4,239
-
47
15-24 4,716 19.5 101 2,224 1,718 77%15-24 635 28.6
2. ()
3. 5
4. 101 10 0,198
5. 96 101 46 101 12,554
-
48
6. 101 11 21 () 928 415 1 101 11 24 4,000 333 91.39% 100
() 1. 101 7 1 102 3 13
412 35 (1,306 130 ) AH3
2. 101 11
3. 101 297 5,365 101 10 1 65 6 6 102 1 50-64
-
49
101 12 26 65 102 3 11 282.7 97.6%
4. 10-15% 101 12 1 102 3 31
5. 101 100 14
6. 101 1,247 H5N2 2.39 H5N2
7. 101 3 1 8 31 101
-
50
A/H5N1 9,761
() 1. 101
101 492
2. 102-104
3. 101 59 9()
4.
5. WHO 555
-
51
5 ( 5 )
() 1. 101 55
(PCV)(102) 3 2-5 PCV
2. 101 4 101 9 MMR Tdap-IPV
3. 75
-
52
() 1.
2. 101 12 649 100 3 3 96 101 12 7
() 1. 101100
186 94.04% 1 98.35%101 1-6 104 97%
2. 99 100 101 4 15 500 12 509 97.7% 374
-
53
66.8 13 2,430 91.0%
3. 101 1 12 5 1,825 1,399 23 3,118 99.7%3,600 10,697 3,887
4. 101 163 75.1%100 71.4% 100 45.6% (93 24%97 35.1% 2025 50%) 99 11 24 101 12 1,788 100%
5.
-
54
28 4 1 10 50 101 4 5 101 795 156 6 2 99 1.090100 1.079 16 3 12101 1.074 25 15
6. 101 17,088 774,38720-49
-
55
72,827
() 1. 4 5
101 1 12 35 1,845 96% 98%
2. 99 101 3 15 700 12 309 95.6%(175 )(134 ) 17 380 89.4% 216
3. 5 1 100 30 9,118 101 6 16 7,794 101 7 18 101 22 2,659 146
4. 7 7 99 103 1 1
-
56
98.3%100 100 80%100 1 1 98%101 1-6 55 7 84% 100
5. e101 44 5,903 2,221 39 Teens 9 4,044 113 / 120 2 1,750 61 64 521 msn 131
() 1. 40 64 3 155
65 1101 179 100 177
2. 101 101-102
-
57
3. 101 18 58.1% 43.6%
4. 101 20 33 1 8 2,917 3 8,543 5 8,802 90%
5. 101 Healthy Lifestyle Healthy Blood Pressure 1,014 887 1,989
6. 100-104101-103
7.
-
58
8. 101 524
9. 490101 186 22
10. 101 131 50 33 3,808 12 65 101 7 9 8,206 45 5,922
11. 101 65 87.1 101 50 69 51 50-69 101.265 269 101
-
59
1-10 4,574
12. 101 22 367 1,435 458 1,454 80% 75%
13. 199
101 12 38
2101 40
3 101 28 268
-
60
4101 4 11 20 WHO Working Group on HPH and Age-Friendly Health Care
14. WHO-100 9 101 20 101 22 APEC 101 8 28-29 2012 APEC APEC 101 9
-
61
10 4 101 12 1112 360
15. 101 22 1,905 7 4 3
() 1.
Alliance For Healthy Cities, AFHC 101 1011 AFHC 10 11 101
-
62
AFHC(Award for Creative Developments in Healthy Cities)
2. 1 101 12 93 WHO
2 101 WHO-HPH Recognition Project 21
3 101 4 11-13 2012 20 598 3
4 101 () 2
5 101 3 73 84
3. 101 18 142 ( 38.6
-
63
5
4. 94 101 28 101 12 19
5. 101 12 9,186 342
6. 1 3,699
101 214
-
64
(WHO IUHPE Mr.Ian YoungNoy S Kay Robert F. Valois Lawrence Harry St Leger ) 4 14 120 138
2 101 78
7. 1 101 6
9,345
2 100
8. 100 101 12 31
-
65
1726 101 632 ( 36.6%)237 101 1 10 1 867 57
() 1. 100 22
100 101 101 22 101 12 7,012 77 9,303 1,137 60 600
2. 368
3.
-
66
0800-367-100101 -
4. 1 18 100 65.1%
101 70.8%
2 100 22 1035 138 101
5. 1
2 101 18 142
-
67
() 1. 101
97 21.9% 18.7% 97 23.7% 8.3%
2. 101 12 1016,0759,2308,254 3,497 8,000
3. APP
4. 101 113 2012 65
5. 101 5 (DG SANCO) Ms. Paola Testori Coggi
-
68
37 1
6. 200 101 12 97% 99.7101 9 88 90 3-10 100 36,223 101 48,530 34.0% 100 9,708 101 15,433 59.0%
7. 101 9.8 2012 3 1,067
8. 49 6.5 9,706 100 101 1 2,800 79.5%
9. 98 101 114 2,621
-
69
() 1.
18 96 17.2% 101 10.9%
2. 97 174.4 100 173.7 0.4% 97 10 94.4 100 93.4 1.1% 105 10%
3. 92 96 41% 94 98 43% 2% 58% 60% 2%
4. 101 491 213.5 67 112.3 98.2 4,045 9,637 3,166 2,001 2 3,775 1,232 3,445
5. 101 1 1 3 1 3
-
70
HPV 2,020 3 94.1% 20.3% 1,348 3 98.5% 64%
6. 222 69
7. 101 37 101 47
8. 73 101 2 99 1 42% 98 39%3%
() 1.
100 2,954 101
-
71
101 6 8,021
2. 101 78 279 123 308 10 33 6,034
3. 101 45 45 90101 15,911 872 10,954
4. 101 1 12 11,880 693
5. 101 12 193 82
-
72
40 101 12 3,813 20 101 12 36 95,000101 302 17 101 161 373 31 565
6. 101 7
() 1.
101 749 34
-
73
2. : 100 547 538 98.4%
3. 907 889 () 307 1196
4. 101 100 11%
() 1. 5
1 4 101 : 404 132 137
2. 8 101 82 5,832
() 1. 71 (EV71) 101 3
1 2 102 1
-
74
2. (HPV) HPV
3. (RSV)
4. 10111 104
5. B TFDA 101 11
-
75
IND
6. 5-MTP 50%
7. 7 14,000 3
8. DBPR108 101 1 101 32
9.
-
76
10. 101 600
() 1.
65 (Toward Universal Coverage) WHA (2005)
-
77
1610 101 5 24 DG SANCO(WMA)(WHPA)
2. 101
3. APEC(2011 2012)APEC (HWG)(Health Policy Dialogue) 2012 APEC (APEC High-Level Meeting on Health and the Economy)(A Life Course Approach to Reducing the Economic Burden of Disease)Johnson & Johnson
4. APEC (Workshop on Cost-effectiveness of Strategies for Human Security) APEC
-
78
101 8 5. 2012 2012 Taiwan Health Forum
11 14 15722 42 Enrique T. Ona David Learmonth Masato Mugitani(APHA)(WFPHA)(APACPH)(WMA)WHO (UNDP)(SADC)(World Health Assemble, WHA)
() 1. 101
12
-
79
2. Non-communicable
Disesses-Global priorities and solutions
3. (1) 101 8 7
11
(2) (TaiwanIHA)(AMDA) 100 8 130 130 101 2 1
(3)
-
80
4.
100 6 26
101 8 1
WHO IHR 4 () 9
-
81
5. (1) ()
e-Health (2)
(3) 101 761
() 1. 101
20 121 101 8 8 50
2. 101 30 22
() 3
-
82
() 101711,153
101 101/03/01 Pham Van Thuc 6 101/04/0910
Esperanza Martinez 2
101/05/01 Hon. Jenniffer A. Gonzalez-Colon 6
101/07/25 Excmo. Lic. Gudy Rivera Estrada 7
101/07/27 Dr. Douglas Slater Mr. Andreas Wickham 2
101/09/11 Mr. Jean-Pierre Mazery 6
101/10/04 Erika Jurinova 6
101/11/13
Dr. Enrique T. Ona Dr. David Kabua Dr. Cecil B. Wilson Dr. Antonyia Parvanova 2012 24
101/11/15 David Learmonth
101/12/28 Ms. Pia Kjaersgaard 4
101 368 441
-
83
104 93 106 26 6 9 71 1,153
() ISO
1. ISO 9001: 2008 101 11 9 BV Cert.
2. 101 ISO 9001
() 2011 3.1(GRI G3.1) 2011 1
-
84
2012 12 102 1 24
() 1. 1
2 3 2. 1 2 3
-
85
4 102 6 12 3
5
() 1.
2. 3. 1
call center
2 3 GTF-CCC(Global Task Force-Cancer Care and
Control) 4
() 1. 1
-
86
2 3 2. 1 2 3. 1 2
2
3 4
() 1. 2. 55 64 3.
4. 5.
6.
HPV 7.
-
87
() 1.
2. 3. CDC
EUROCAT 4. 5. Gastein European Health Forum
()
12 18 752
()
-
88
82 1 101 10 16 12 18
()
()
() 1.
-
89
2.
3. 101 12 3 102 3
() 1.
2.
3. 4. 102
5.
-
90
() 2143 1670
() 1.
2. 3. 4. 5.
()
()
-
91
1.
2. IDS
3. (101-105 )
4.
() 1.
2. 102
()
-
92
1. 4.91%
105
2.
3.
() 1.
2.
() DRG
-
93
1. DRG
2.
() 1.
2. 73
3. () 1 3 6 4 5 4 6 2 10 (1)
-
94
(2)(3)(4)(5)(6) 102 2 22
() 102 1 1 102
1.
2.
3. NGO
4.
-
95
() 1.
()102 2
2.
3. 102 20 103 40
4.
()
() 1.
2.
3. 4.
-
96
100% 5.
() 1. 71
2. 71
()
()
() 104 PCV (ACIP)
-
97
() (DMF)
()
()
1.
2.
-
98
()
1.
2.
()
()
()
-
99
()
() 1. 102 2.
() 1.
2.
-
100
3.
() 1.
2.
() 1.
2.
()
-
101
() ()
()
()
()
() () ()
()
() () () () ()
-
102
82 1
-
1102318
Department of Health
2
-
3
3
4
-
5(1/15)
()190222677
()
()152818095%
()CPR+AED22215,00036()AED
(26)11411
(50)111920
(13)139
(39)41223
(27)31311
(35)61613
6
(2/15)
100 101
510 831
1,381 1,325
13 16,397 19,113
48 45
2,134 1,000
(OSCE) 102 102
-
7()1.1021131,2284.01
2.1011,1821021841015210215
()1.10812,0002.
(3/15)
10100
1011-123,4613,50746
()
8
-1()
91()2012
1014,61159,74612
()175851
()511
()10110122318837
(4/15)
-
9(5/15)-2()
()1
()610
1. 10191()20010164%
2. 10112141,007(1014)4,592
3. 1015122,829
4. 3060102125
5. 102
10
(6/15)-3()
1013,728101802,48810213()
()
302()27,508()102
-
11
(7/15)()10110
37,16810012932.8461.6
()10151213326
()101103915,00010,000
12
(8/15)()
1.
2. AED
()1.
2. 821
-
13
(9/15)-1()
()
10111710911610
()2495310112 4954,593
14
(10/15)-2()
1.101710211
2.1013.101111027
4.10110216
5.1,943(1,7242163)
-
15
(11/15)-3
()H1N1
()1001101127
8,60210,73189,333
()----
16
(12/15)
()101282
()101207
()101191
()101197
183
-
17
(13/15)
()1.HIS101301872.PACS1012393.1016,906
()101277()101-105206()86()()
1013()38()
18
(14/15)()
1.(22)(63)(368)
2.()
1.10117,0212.10113102
2010340()
6527%(16%)9712113,202
()
-
19
(15/15)
()
()
()1.
2.
3. 4.
20
()10211
()
()()102314
4,241
(1/6)
-
21
()
10112258219
()
(2/6)
3,589 2.14 130,219 31.8 4,755 2,274 43,000 3.53
10111 3,787 1.1 43.4
22
()
(3/6)
-
23
18.144
101.6 65
101.7~8 501.52
101.9~10 401.52
101.11~12
18.0
14.8
9.5
4.0
0
5
10
15
20
101.6 101.7~8 101.9~10 101.11~12
(4/6)
24
(5/6)
()(DRG)1.4.394.132.
()8()20100710312
3()
10121.4710250.552.22
()(RBRVS)102
-
25
()1. 1011026.7
2. 10149700-15003. 10224
()(IDS)1. 881012. 483. 25296
()1. 92101452. ()3. 101793363110
(6/6)
26
(1/6)
()1.1117-131(101.8.8)2.(101.8.27)
()1.(101.9.6)
2.(101.8.9)3.101721()
() 2
-
27
(2/6)
()()50111,253
()()
http://fadenbook.fda.gov.tw fa: food additives d: data en: exhibition book:
28
(3/6)
()61637
()24898
()1. 5722,3632. 16091
()1.33,550
99.8%(101.9.12~101.11.20)2.446(101.9.11~101.11.18)
-
29
(4/6)
()PIC/S GMP1.102(PIC/S)2.45
()1.GMP(101.6.27)
2.27110163.(101.4.5)
()256
()221734
69
30
(5/6)
()10116,21622(1.25%)
()10118,22510016,6549.4%
()13.9%
4.71 % ()
21.9%14.4 %
-
31
()()101
300
101.8.110101
8574,682
10 32%10+18 45%
(6/6)
32
() WHO101924
159
(1/6)
()1. WHO
2.10/33.104.5.6.
-
33
(2/6)
()101153(2)1023131
()
87~101
34
(3/6)
()102 15
()
99 100 101
99101
-
35
()
35.6%90%
94~1001. 94
2. 20123. 2012
(3/6)
()1.2.
3.4.
36
()101
24,2392,2241,71877%
()1.
2.
3.4.5.
(4/6)
-
37
() 10171102313412
35 (1,306130)
()
(5/6)
0
6
12
18
24
30
0
1
2
3
4
5
2012
/27 30 33 36 39 42 45 48 51
2013
/2 5 8 11 14 17 20 23 26
Consultation Week
2012/2013-OPD 2011/2012-OPD 2012/2013-ER 2011/2012-ER
%of
Outpa
tient
Visits
for IL
I
(%)
% of
ER Vi
sits f
orILI
(%
)
1.24
10.61
38
(1/6)
()1011-61041097.0%
() 10191%2.5
() 10189.4%216
()101233,11899.7%3,917
()10116375.1% (10071.4%)
() 1011.074 2592310115
-
39
(2/6)
()1011-655784% (10080%)
()2,6591466
() 101179(100177
)()
101743()3674581,473
()10138
10013()101201009
10222
40
(3/6)
() 1011011WHO
() 1019376WHO
() 10114238.6%
()10119WHO()1019,186
(1007,411)()138
78-101
7,012781,137600
-
41
(4/6)
()1011016,0758,25434978,000
()11310165
()1. 97%
2. 8890
3. 1019.84. 492,800
178.5% ()
1. 10118.7% 9721.9%2. 1018.3%9723.7%
42
(5/6)
() 1817.2%10.9% (96vs101)
() 0.4%1.1% (97vs100)
() 2% (96vs98)
() 101491(102
981.6)13.6()
3942%(98vs99)1012(1001,000)
-
43
(6/6)()
10168,021()
101788336,034
()4516,072
11,220()
10111,880 ()
5,855
()1017
44
(1/3)
101749
()10098.4()9071,196()10110011%
()5
404132PI137
()8825,832 :+
:
-
45
(2/3)
()711021
()
()
()H5N1
()101
46
(3/3)
()
()5
()
()
-
47
(1/6)()65
(Toward Universal Coverage)
()
48
(2/6)APEC() (20112012)APEC(HWG)
(Health Policy Dialogue)
() 2012APEC(APEC High-Level Meeting on Health and the Economy)Johnson &Johnson
-
49
(3/6)()
()
50
(4/6)
()
()
()1019
WHO IHR
()101
-
51
(5/6)2012
10111141572242
52
101/03 Pham Van Thuc6
101/04 Esperanza Martinez2 101/05 Hon. Jenniffer A. Gonzalez-Colon6 101/07 Excmo. Lic. Gudy Rivera Estrada7
101/07 Dr. Douglas SlaterMr. Andreas Wickham2
101/09 Mr. Jean-Pierre Mazery6
101/11
Dr. Enrique T. OnaDr. David Kabua 201224
101/11 David Learmonth
101
711230373223
(6/6)
-
53
ISO ()101119ISO 9001: 2008
()101ISO 9001
(CSR)
102124
54
(1/2)
-
55
(2/2)
56
()()
()()
()()()
-
57
57
58
58
()()()()
() IDS()() ()
-
59
60
()()()()()
()()
-
61
62
-
63
63
64
64
-
65
66
-
67
821
32321362424128 9596100
68
-
-
69
70